[go: up one dir, main page]

CA2337507A1 - Composition pour le traitement du stress - Google Patents

Composition pour le traitement du stress Download PDF

Info

Publication number
CA2337507A1
CA2337507A1 CA002337507A CA2337507A CA2337507A1 CA 2337507 A1 CA2337507 A1 CA 2337507A1 CA 002337507 A CA002337507 A CA 002337507A CA 2337507 A CA2337507 A CA 2337507A CA 2337507 A1 CA2337507 A1 CA 2337507A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
day
administered
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002337507A
Other languages
English (en)
Inventor
Judith J. Wurtman
Richard J. Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2337507A1 publication Critical patent/CA2337507A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé relatif au traitement du stress chez un patient présentant des symptômes liés au stress, qui consiste à administrer au patient une quantité efficace de médicaments sérotoninergiques. L'invention concerne en outre des exemples spécifiques de cette catégorie de médicament, à savoir entre autres, le lithium, la chlorimipramine, la fluoxetine, la fluvoxamine, la sertaline, ainsi que les médicaments MK-212, Ro 60-0332/ORG 35035, Ro 60-175/ORG 35030, la d,1-fenfluramine, la dexfenfluramine, ou des sels correspondants.
CA002337507A 1998-07-16 1999-07-16 Composition pour le traitement du stress Abandoned CA2337507A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9301398P 1998-07-16 1998-07-16
US60/093,013 1998-07-16
PCT/US1999/016153 WO2000003701A1 (fr) 1998-07-16 1999-07-16 Composition pour le traitement du stress

Publications (1)

Publication Number Publication Date
CA2337507A1 true CA2337507A1 (fr) 2000-01-27

Family

ID=22236330

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002337507A Abandoned CA2337507A1 (fr) 1998-07-16 1999-07-16 Composition pour le traitement du stress

Country Status (4)

Country Link
EP (1) EP1096927A4 (fr)
JP (1) JP2002520353A (fr)
CA (1) CA2337507A1 (fr)
WO (1) WO2000003701A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US20050165006A1 (en) * 2002-04-03 2005-07-28 Dae-Yoon Chi Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
CA2483093A1 (fr) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress
RU2617512C1 (ru) 2015-10-23 2017-04-25 Общество с ограниченной ответственностью "Нормофарм" Средство с антистрессовой, анксиолитической и антидепрессивной активностью и композиция на его основе
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
EP4031529B1 (fr) * 2020-12-01 2023-09-27 Small Pharma Ltd Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1593659A1 (ru) * 1983-12-29 1990-09-23 Московская ветеринарная академия им.К.И.Скрябина Способ профилактики стрессов у цыпл т
JPH06699B2 (ja) * 1984-08-11 1994-01-05 カネボウ食品株式会社 精神安定チユ−インガム
HU202108B (en) * 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
KR950700063A (ko) * 1992-02-21 1995-01-16 베르너 발데크 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
PT1153603E (pt) * 1993-06-28 2007-01-31 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
FR2710916B1 (fr) * 1993-10-04 1995-12-22 Pasteur Institut Composés de nature peptidique ayant une activité modulatrice de la réponse sérotoninergique; applications diagnostiques et thérapeutiques.
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
JPH0940648A (ja) * 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd 新規な８−（２−アミノアルコキシ）キノリン誘導体
US5852020A (en) * 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder

Also Published As

Publication number Publication date
JP2002520353A (ja) 2002-07-09
EP1096927A4 (fr) 2002-09-04
EP1096927A1 (fr) 2001-05-09
WO2000003701A1 (fr) 2000-01-27

Similar Documents

Publication Publication Date Title
US6579899B1 (en) Composition for treatment of stress
Collins et al. Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11. 3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes
CN104127434B (zh) 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
US11642326B2 (en) Prevention or remediation composition for dementia or depression
JP2010275314A (ja) 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
US20090203731A1 (en) Treatment of depression and other affective disorders
EP3458060B1 (fr) Polythérapie pour un dysfonctionnement sexuel chez l&#39;homme
CN113939276A (zh) 用于治疗精神障碍、行为障碍、认知障碍的药物组合物和方法
JP2024513581A (ja) 本態性振戦の治療
CA2337507A1 (fr) Composition pour le traitement du stress
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性
JP2024533015A (ja) 脱髄性の疾患および病状の処置のためのフェンフルラミン
MX2008000248A (es) Combinaciones de eszopiclona y un antidepresivo y metodos de tratamiento contra la menopausia y trastornos del estado de animo, la ansiedad y trastornos cognitivos.
EP2694065B1 (fr) Composition pour le traitement de la baisse du désir sexuel
US20090281112A1 (en) Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
JPH0930959A (ja) 後壁心筋梗塞治療へのサートラリンの使用
TW200836718A (en) Method of treatment of obesity using low doses and dose-escalation
US20200121651A1 (en) Pramipexole for Use in the Treatment of Pain
CN101156850A (zh) 抑郁症和其他情感障碍的治疗
Rubino et al. A review of topiramate and phentermine: a combined therapeutic approach for obesity
WO2025245066A1 (fr) Compositions et méthodes pour influer sur la perte de poids, la gestion du poids, les troubles sexuels, le bien-être, l&#39;estime de soi et/ou la confiance en soi
KR20190090509A (ko) Trpv4 길항제를 포함하는 척수 손상 예방 또는 치료용 조성물
TWI292314B (fr)
US20130267533A1 (en) 5ht1a agonists for treatment of high cholesterol
Tablets et al. PrZOLMITRIPTAN ODT

Legal Events

Date Code Title Description
FZDE Dead